[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer
-
- STATUS
- Not Recruiting
Summary
The purpose of this research study is to test if an imaging drug, not approved by the Food and Drug Administration (FDA), called FES, is useful for evaluating your type of cancer and predicting how well your cancer responds to therapy.
Description
This phase II trial studies F-18 16 alpha-fluoroestradiol (FES) positron emission tomography (PET)/computed tomography (CT) in predicting response to endocrine therapy in patients with newly diagnosed breast cancer that has spread to other parts of the body (metastatic).
Details
| Condition | breast cancer |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX7977 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.